Estrogen withdrawal, increased breast cancer risk and the KRAS-variant

摘要: The KRAS-variant is a biologically functional, microRNA binding site variant, which predicts increased cancer risk especially for women. Because external exposures, such as chemotherapy, differentially impact the effect of this mutation, we evaluated association estrogen breast (BC) and tumor biology in women with KRAS-variant. Women BC (n = 1712), subset 286) unaffected controls 80) were evaluated, hormonal status, pathology compared. withdrawal on transformation isogenic normal cell lines or without was studied. Finally, presentation characteristics multiple primary (MPBC) evaluated. patients more likely to have ovarian removal pre-BC diagnosis than non-variant (p 0.033). In addition, also appeared lower state controls, BMI (P < 0.001). hormone replacement therapy (HRT) discontinuation associated triple negative Biologically confirming our clinical findings, acute led oncogenic positive lines. had greater an 11-fold presenting MPBC compared (45.39% vs 6.78%, OR 11.44 [3.42-37.87], P Thus, low appear increase predict aggressive KRAS-variant, who are significantly present cancer.